NCT02328261View on ClinicalTrials.gov

A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

April 30, 2017

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Icotinib

Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY